OQROSign up free
Insider trade

Vertex Pharmaceuticals (VRTX): Officer sold ~$143K

Ourania Tatsis, Officer at Vertex Pharmaceuticals, sold ~$143K of Vertex Pharmaceuticals shares.

~$143K
Approx. value · 310 sh @ $459.83
64K
Holds after · shares reported
Traded
Feb 11, 2025
Filed
Feb 12, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

  1. Dec 13, 2024FDAFDA drug approval: Orkambi
  2. Dec 13, 2024FDAFDA drug approval: Orkambi
  3. Dec 20, 2024FDAFDA drug approval: Alyftrek
  4. Dec 20, 2024FDAFDA drug approval: Trikafta (Copackaged)
  5. Dec 20, 2024FDAFDA drug approval: Trikafta (Copackaged)
  6. Jan 30, 2025FDAFDA drug approval: Journavx
  7. Feb 11, 2025 · this disclosureInsiderOfficer sold ~$143K of VRTX shares in the open market

What came next

  1. Feb 11, 2025Insider · 3 peopleInsiders: 3 sales (~$3.0M)
  2. Feb 18, 2025Insider · 3 peopleInsiders: 3 sales (~$1.2M)
  3. Feb 20, 2025InsiderOfficer sold ~$533K of VRTX shares in the open market
  4. Feb 24, 2025CongressDisclosed purchase of VRTX — reported range $15,001 - $50,000
  5. Feb 25, 2025Insider · 4 peopleInsiders: 4 sales (~$1.9M)
  6. Feb 27, 2025Insider · 3 peopleInsiders: 3 sales (~$2.1M)
  7. Mar 3, 2025InsiderOfficer sold ~$1.58M of VRTX shares in the open market
  8. Mar 4, 2025InsiderOfficer sold ~$1.97M of VRTX shares in the open market
  9. Mar 10, 2025Insider · 3 peopleInsiders: 3 sales (~$4.9M)
  10. Mar 13, 2025InsiderOfficer sold ~$1.65M of VRTX shares in the open market
  11. Mar 13, 2025CongressDisclosed purchase of VRTX — reported range $15,001 - $50,000
  12. Mar 20, 2025Congress · 1 personMembers of Congress: 2 sales
  13. May 2, 2025InsiderDirector sold ~$202K of VRTX shares in the open market
  14. May 15, 2025InsiderOfficer sold ~$22K of VRTX shares in the open market
  15. May 22, 2025FDAFDA drug approval: Kalydeco
  16. May 22, 2025FDAFDA drug approval: Kalydeco
View the official recordSEC Form 4

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Vertex Pharmaceuticals

For Vertex Pharmaceuticals, OQRO holds 3 insider filings (SEC Form 4 or Form 144) and 1 Congress trade report dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its VRTX page.

Other recent filings by Ourania Tatsis, EVP, Chief Reg. & Quality Off.

The full history of Ourania Tatsis, EVP, Chief Reg. & Quality Off. is on the profile page.

How this filing works

Explore the data

Other disclosures at Vertex Pharmaceuticals

Everything OQRO holds on this company is on its VRTX page.

This is one filing. OQRO holds the rest

Insider trades filed with the SEC, stock trades disclosed by members of Congress, fund holdings from 13F filings and federal contract awards, each one in plain words next to its official filing. On this page it opens why the trade stands out, what the company did around that time, the price since, and every field of the form.

Sign up freeAlready have an account? Log in

OQRO is free for everyone. No card, no trial

OQRO describes public disclosures and context calculated from them. It does not give personalized advice and does not recommend any transaction. How OQRO treats data